Galectin Tanks as NASH Drug Flunks Phase IIb Trial
There was a positive trend in the total group of patients but the difference did not reach statistical significance for this primary endpoint. Source: BioSpace
There was a positive trend in the total group of patients but the difference did not reach statistical significance for this primary endpoint. Source: BioSpace
Five researchers were touted for their work in life sciences. Source: BioSpace
Tamid enters exclusive licensing deal with UNC-Chapel Hill for three preclinical gene therapy product candidates. Source: BioSpace
LifeOmic is planning to build new headquarters at the Indiana University Emerging Technology Center. Source: BioSpace
Pfizer is no stranger to taking the big gambles-note the company's attempts to buy Astra in 2014 and Allergan in 2016. Source: BioSpace
The patients who were transfusion dependent and switched from Soliris were forced to switch back to the Alexion drug. Source: BioSpace
The first $150 million is available immediately and an additional tranche of $50 million is available for draw by March 2019. Source: BioSpace
Rick Duprey, writing for The Motley Fool, takes a look at three biotech stocks that have quadrupled this year. Source: BioSpace
The Board of Directors also stated that it would endeavour to have a final clarification of the Company’s future by the end of 2017. Source: BioSpace
Between 2015 and 2016, the number of GMP inspections conducted by European Economic Area authorities of non-EU sites dropped by nearly 25 percent, but the authorities reported more findings of…